Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

The group of so-called “Magnificent 7” mega-cap tech giants continue to dominate the mind share of most investors, with these ...

If you’re like most income investors, you’re on the hunt for stocks and funds that can stand up to a storm these days. I'm ...

Looking ahead, revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

Between January and December 2024, Meesho’s content commerce initiative has reached over 14.5 million users. This strategy has driven nearly 10X growth across key categories such as women’s western ...

With the Super Bowl officially wrapped up, and the Eagles taking the mantle away from the Chiefs in an epic showdown (beat ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...